Alphatec/$ATEC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alphatec
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.
- Ticker
- $ATEC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 913
- Headquarters
- Carlsbad, United States
- Website
- www.atecspine.com
Alphatec Metrics
BasicAdvanced
$1.6B
-
-$0.72
0.85
-
Price and volume
Market cap
$1.6B
Beta
0.85
52-week high
$23.29
52-week low
$6.82
Average daily volume
2.2M
Financial strength
Current ratio
1.887
Quick ratio
0.993
Long term debt to equity
46.16
Total debt to equity
52.369
Interest coverage (TTM)
-0.80%
Profitability
EBITDA (TTM)
38.364
Gross margin (TTM)
70.84%
Net profit margin (TTM)
-13.50%
Operating margin (TTM)
-4.76%
Effective tax rate (TTM)
-0.24%
Revenue per employee (TTM)
$890,000
Management effectiveness
Return on assets (TTM)
-3.07%
Return on equity (TTM)
-373.44%
Valuation
Price to revenue (TTM)
2.01
Price to book
-134.98
Price to tangible book (TTM)
-9.33
Price to free cash flow (TTM)
-285.5
Free cash flow yield (TTM)
-0.35%
Free cash flow per share (TTM)
-0.037
Growth
Revenue change (TTM)
19.47%
Earnings per share change (TTM)
-36.92%
3-year revenue growth (CAGR)
24.55%
10-year revenue growth (CAGR)
19.88%
3-year earnings per share growth (CAGR)
-22.12%
10-year earnings per share growth (CAGR)
-28.89%
What the Analysts think about Alphatec
Analyst ratings (Buy, Hold, Sell) for Alphatec stock.
Analyst projections of the future price of Alphatec stock.
Bulls say / Bears say
The core surgical business is still gaining traction: Q2 surgical revenue grew 17%, with case volumes up 20% and net new surgeon users up 24%. (Alphatec)
Profitability is improving alongside growth: Q2 adjusted EBITDA rose to $36 million, its margin expanded by 420 basis points, and the company generated positive free cash flow. Management also raised its 2026 adjusted EBITDA outlook to about $140 million. (Alphatec)
Recent FDA clearances for intraoperative alignment and an automated rod bender broaden the Valence technology platform, potentially making Alphatec’s surgical offering more integrated. (Seeking Alpha)
Profitability remains fragile: Q2 still produced a $25.8 million GAAP net loss, while debt principal was $685 million at quarter-end, leaving the company exposed if operating progress stalls. (StockTitan)
Higher procedure volumes are not fully translating into sales: average revenue per case fell about 2.7% in Q2, with biologics attachment still below year-earlier levels. (The Motley Fool)
EOS remains a weak spot: Q2 revenue was $17 million and essentially flat year on year, while EOS Insight had reached only about 15–20% of the installed fleet, making growth dependent on a still-early rollout. (ROIC AI)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
Alphatec Financial Performance
Revenues and expenses
Alphatec Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alphatec News
AllArticlesVideos
Funds containing Alphatec
AllEURGBPUSD
Fund name | Fund size | $ATEC weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.13% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.